These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 10839598)

  • 1. CD8 T cell anti-HIV activity as a complementary protective mechanism in vaccinated chimpanzees.
    Leno M; Kowalski M; Robert-Guroff M
    AIDS; 2000 May; 14(7):893-4. PubMed ID: 10839598
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group.
    Corey L; McElrath MJ; Weinhold K; Matthews T; Stablein D; Graham B; Keefer M; Schwartz D; Gorse G
    J Infect Dis; 1998 Feb; 177(2):301-9. PubMed ID: 9466515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees.
    Bruck C; Thiriart C; Fabry L; Francotte M; Pala P; Van Opstal O; Culp J; Rosenberg M; De Wilde M; Heidt P; Heeney J
    Vaccine; 1994 Sep; 12(12):1141-8. PubMed ID: 7998425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.
    Bures R; Gaitan A; Zhu T; Graziosi C; McGrath KM; Tartaglia J; Caudrelier P; El Habib R; Klein M; Lazzarin A; Stablein DM; Deers M; Corey L; Greenberg ML; Schwartz DH; Montefiori DC
    AIDS Res Hum Retroviruses; 2000 Dec; 16(18):2019-35. PubMed ID: 11153085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with a Shigella DNA vaccine vector induces antigen-specific CD8(+) T cells and antiviral protective immunity.
    Shata MT; Hone DM
    J Virol; 2001 Oct; 75(20):9665-70. PubMed ID: 11559798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
    Bower JF; Green TD; Ross TM
    Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization.
    Lubeck MD; Natuk R; Myagkikh M; Kalyan N; Aldrich K; Sinangil F; Alipanah S; Murthy SC; Chanda PK; Nigida SM; Markham PD; Zolla-Pazner S; Steimer K; Wade M; Reitz MS; Arthur LO; Mizutani S; Davis A; Hung PP; Gallo RC; Eichberg J; Robert-Guroff M
    Nat Med; 1997 Jun; 3(6):651-8. PubMed ID: 9176492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of gp120-specific immune responses by genetic vaccination with the human immunodeficiency virus type 1 envelope gene fused to the gene coding for soluble CTLA4.
    Nayak BP; Sailaja G; Jabbar AM
    J Virol; 2003 Oct; 77(20):10850-61. PubMed ID: 14512535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular immune responses in asymptomatic human immunodeficiency virus type 1 (HIV-1) infection and effects of vaccination with recombinant envelope glycoprotein of HIV-1.
    Gorse GJ; Simionescu RE; Patel GB
    Clin Vaccine Immunol; 2006 Jan; 13(1):26-32. PubMed ID: 16425996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prime-boost immunization strategies against HIV.
    Barnett SW; Klinger JM; Doe B; Walker CM; Hansen L; Duliège AM; Sinangil FM
    AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S299-309. PubMed ID: 9814958
    [No Abstract]   [Full Text] [Related]  

  • 11. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2017 May; 91(9):. PubMed ID: 28179536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus.
    Robert-Guroff M; Kaur H; Patterson LJ; Leno M; Conley AJ; McKenna PM; Markham PD; Richardson E; Aldrich K; Arora K; Murty L; Carter L; Zolla-Pazner S; Sinangil F
    J Virol; 1998 Dec; 72(12):10275-80. PubMed ID: 9811775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the V3 loop deletion of envelope glycoprotein on cellular responses and protection against challenge with recombinant vaccinia virus expressing gp160 of primary human immunodeficiency virus type 1 isolates.
    Kiszka I; Kmieciak D; Gzyl J; Naito T; Bolesta E; Sieron A; Singh SP; Srinivasan A; Trinchieri G; Kaneko Y; Kozbor D
    J Virol; 2002 May; 76(9):4222-32. PubMed ID: 11932387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.
    Graham BS; Matthews TJ; Belshe RB; Clements ML; Dolin R; Wright PF; Gorse GJ; Schwartz DH; Keefer MC; Bolognesi DP
    J Infect Dis; 1993 Mar; 167(3):533-7. PubMed ID: 8095059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge.
    Doria-Rose NA; Ohlen C; Polacino P; Pierce CC; Hensel MT; Kuller L; Mulvania T; Anderson D; Greenberg PD; Hu SL; Haigwood NL
    J Virol; 2003 Nov; 77(21):11563-77. PubMed ID: 14557642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic T lymphocyte and helper T cell responses following HIV polynucleotide vaccination.
    Shiver JW; Perry HC; Davies ME; Freed DC; Liu MA
    Ann N Y Acad Sci; 1995 Nov; 772():198-208. PubMed ID: 8546393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
    Dis Markers; 1991; 9(1):51. PubMed ID: 1742945
    [No Abstract]   [Full Text] [Related]  

  • 18. Construction, biological activity, and immunogenicity of synthetic envelope DNA vaccines based on a primary, CCR5-tropic, early HIV type 1 isolate (BX08) with human codons.
    Corbet S; Vinner L; Hougaard DM; Bryder K; Nielsen HV; Nielsen C; Fomsgaard A
    AIDS Res Hum Retroviruses; 2000 Dec; 16(18):1997-2008. PubMed ID: 11153083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160.
    Lee D; Graham BS; Chiu YL; Gilbert PB; McElrath MJ; Belshe RB; Buchbinder SP; Sheppard HW; Koblin BA; Mayer KH; Keefer MC; Mulligan MJ; Celum CL
    J Infect Dis; 2004 Sep; 190(5):903-7. PubMed ID: 15295694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques.
    Cho MW; Kim YB; Lee MK; Gupta KC; Ross W; Plishka R; Buckler-White A; Igarashi T; Theodore T; Byrum R; Kemp C; Montefiori DC; Martin MA
    J Virol; 2001 Mar; 75(5):2224-34. PubMed ID: 11160726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.